Effect of an in-hospital multifaceted clinical pharmacist intervention on the risk of readmission – APhA submits compounding comments to FDA.

7Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Effect of an in-hospital multifaceted clinical pharmacist intervention on the risk of readmission – APhA submits compounding comments to FDA. – (866) 348-2889

A multifaceted clinical pharmacist intervention could reduce the number of visits to the emergency department (ED) and readmissions to the hospital, according to new research. The clinical trial involved more than 1,400 Danish adults in an acute admission ward who were using five or more medications. The patients were randomized into three groups: usual care (no intervention), a basic intervention (medication review), and an extended intervention (medication review, three motivational interviews, and followup with the primary care physician, pharmacy, and nursing home.) Compared with the other two groups, the extended intervention had a statistically significant effect on the number of patients who were readmitted within 30 and 180 days after inclusion. The extended intervention also had a significant effect on the number of patients who experienced the primary composite endpoint–readmission or an ED visit within 180 days. There was a nonsignificant reduction in drug-related readmissions within 30 and 180 days after inclusion and in deaths. “This study shows that hospital pharmacists may play an important role in preventing hospital readmissions,” the authors conclude.

CLICK HERE FOR CONTINUE READING

This entry was posted in Pharmacist and tagged , , , . Bookmark the permalink.

Comments are closed.